Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00716521 · ClinicalTrials.gov registry record · Phase 1
Effect Of Treatment With Oral Zolpidem On Polysomnography And Actigraphy Measures In Healthy Volunteers
A Phase 1 study of Methodology Study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT00716521 is a Phase 1 study of Methodology Study that has completed, run by Pfizer. The registered enrollment target is 11 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00716521, a Phase 1 study of Methodology Study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the feasibility of conducting sleep studies in a clinical research unit environment. In addition, the sensitivity of polysomnography and mobile actigraphy technologies will be compared for evaluating sleep stages and sleep architecture.
Conditions Studied
Interventions
- DRUG placebo
- DRUG zolpidem
Study Locations (1)
Connecticut
- Pfizer Investigational Site - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2008-07 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00716521
The ClinicalTrials.gov registry entry for NCT00716521 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Methodology Study appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00716521 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00716521 about?
NCT00716521 is a clinical study titled "Effect Of Treatment With Oral Zolpidem On Polysomnography And Actigraphy Measures In Healthy Volunteers". This study will assess the feasibility of conducting sleep studies in a clinical research unit environment. In addition, the sensitivity of polysomnography and mobile actigraphy technologies will be compared for evaluating sleep stages and sleep architecture.
What is the current status of trial NCT00716521?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2008-07. Estimated completion is 2008-10.
What conditions does trial NCT00716521 study?
This clinical trial studies the following conditions: Methodology Study.
What interventions are being tested in trial NCT00716521?
The interventions under investigation include: placebo (DRUG), zolpidem (DRUG).
Who is sponsoring clinical trial NCT00716521?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00716521 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.